Nobilis Therapeutics said the patent it had exclusively licensed from Partners HealthCare/McLean Hospital, an affiliate of Harvard University, has received a notice of allowance.
The patent is titled “Xenon and/or Argon treatment as an adjunct to psychotherapy for psychiatric disorders” and covers a wide range of noble gas uses in the treatment of psychiatric disorders.
Nobilis Therapeutics CEO Vlad Bogin said: “This patent had laid the groundwork for our first therapeutic indication, which is post-traumatic stress disorder (PTSD).
“As Nobilis Therapeutics has selected the 505(b)(2) pathway to NDA approval, having an issued patent becomes of paramount importance.”
Edward Meloni, one of the inventors, said: “The issue of a patent from the United States Patent and Trademark Office strongly supports the novelty of our safe approach to treating this debilitating and devastating condition — more than 20 veterans a day commit suicide as they try to cope with their traumatic experiences.
“Sadly, current therapies and treatments are only moderately effective.
“We are very excited to have forged this relationship with Nobilis Therapeutics as we work to translate our research findings into a clinical trial and, hopefully, an effective treatment for PTSD.”